Sigma-1 Receptor (SIGMAR1) Signaling in Parkinson's Disease

Sigma-1 Receptor (SIGMAR1) Signaling in Parkinson's Disease

Overview

Sigma-1 Receptor (SIGMAR1) Signaling in Parkinson's Disease describes the role of the sigma-1 receptor in PD pathogenesis and its potential as a therapeutic target. The sigma-1 receptor is an endoplasmic reticulum (ER) chaperone protein localized at ER-mitochondria contact sites (mitochondria-associated membranes, MAMs) that regulates calcium homeostasis, mitochondrial function, and ER stress responses — all key pathways implicated in Parkinson's disease neurodegeneration[1][2].

SIGMAR1 and Parkinson's Disease: The Connection

Genetic Links

Mutations in the SIGMAR1 gene have been implicated in neurodegenerative disorders, and while direct causal mutations in PD are less common than in ALS/FTD, sigma-1 receptor dysfunction contributes to several PD-related pathological mechanisms[3]. The receptor's role in maintaining cellular homeostasis makes it a critical node in PD pathogenesis.

Vulnerable Neurons

Dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable due to their unique physiological characteristics:

• High basal metabolic demand and mitochondrial activity
• Continuous calcium influx during pacemaking
• High ROS production from dopamine metabolism

SIGMAR1 dysfunction exacerbates all these vulnerabilities, making it a critical factor in dopaminergic neuron vulnerability[4].

Mechanism of Action

Ligand Activation

...

Sigma-1 Receptor (SIGMAR1) Signaling in Parkinson's Disease

Overview

Sigma-1 Receptor (SIGMAR1) Signaling in Parkinson's Disease describes the role of the sigma-1 receptor in PD pathogenesis and its potential as a therapeutic target. The sigma-1 receptor is an endoplasmic reticulum (ER) chaperone protein localized at ER-mitochondria contact sites (mitochondria-associated membranes, MAMs) that regulates calcium homeostasis, mitochondrial function, and ER stress responses — all key pathways implicated in Parkinson's disease neurodegeneration[1][2].

SIGMAR1 and Parkinson's Disease: The Connection

Genetic Links

Mutations in the SIGMAR1 gene have been implicated in neurodegenerative disorders, and while direct causal mutations in PD are less common than in ALS/FTD, sigma-1 receptor dysfunction contributes to several PD-related pathological mechanisms[3]. The receptor's role in maintaining cellular homeostasis makes it a critical node in PD pathogenesis.

Vulnerable Neurons

Dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable due to their unique physiological characteristics:

• High basal metabolic demand and mitochondrial activity
• Continuous calcium influx during pacemaking
• High ROS production from dopamine metabolism

SIGMAR1 dysfunction exacerbates all these vulnerabilities, making it a critical factor in dopaminergic neuron vulnerability[4].

Mechanism of Action

Ligand Activation

Sigma-1 receptor is a ligand-operated chaperone. Endogenous ligands include:

• Neurosteroids: Pregnenolone, DHEA
• Sphingolipids: Ceramide

Pharmacological agonists include:

• PRE-084: Selective sigma-1 agonist
• SA-4503 (Cutamesine): Agonist with neuroprotective effects
• Dextromethorphan: FDA-approved cough suppressant with sigma-1 agonist activity

ER-Mitochondria Contact Sites (MAMs)

The sigma-1 receptor is enriched at MAMs — specialized ER-mitochondria contact sites that serve as critical signaling hubs[5]:

Key MAM functions regulated by SIGMAR1:

• Calcium transfer: ER to mitochondria calcium signaling
• Lipid metabolism: Phospholipid exchange
• Mitochondrial dynamics: Fusion, fission, and trafficking
• Autophagy initiation: MAMs serve as phagophore assembly sites

Calcium Dysregulation in PD

The Calcium Hypothesis of PD

Dopaminergic neurons exhibit continuous calcium influx through L-type channels during autonomous pacemaking, creating high basal calcium levels[6]. This makes them particularly dependent on calcium regulatory mechanisms.

SIGMAR1's Role in Calcium Homeostasis

SIGMAR1 modulates calcium signaling through:

IP3 receptor modulation: Regulates ER calcium release

Ryanodine receptor control: Modulates calcium-induced calcium release

Mitochondrial calcium uniporter: Controls mitochondrial calcium uptake

Store-operated calcium entry: Regulates plasma membrane calcium channels

See also: Calcium Signaling Dysregulation in Parkinson's Disease

Mitochondrial Dysfunction in PD

SIGMAR1 and Mitochondrial Quality Control

The sigma-1 receptor plays multiple roles in mitochondrial homeostasis[7]:

| Function | Mechanism | PD Relevance |
|----------|-----------|--------------|
| ATP Production | Optimizes mitochondrial calcium for metabolic enzymes | Reduced ATP in PD neurons |
| Mitochondrial Dynamics | Regulates fusion/fission proteins | Impaired dynamics in PD |
| Mitophagy | PINK1/Parkin pathway modulation | Central PD mechanism |
| ROS Metabolism | Enhances antioxidant responses | Oxidative stress in PD |
| Membrane Potential | Maintains Δψm | Lost in PD |

Link to PINK1/Parkin Pathway

See also: PINK1/Parkin Mitophagy Pathway in Parkinson's Disease

ER Stress and Unfolded Protein Response

SIGMAR1 as an ER Stress Modulator

The sigma-1 receptor acts as a sentinel at the ER, modulating the unfolded protein response (UPR)[8]:

Basal state: SIGMAR1 is bound to BiP (GRP78)

ER stress: Misfolded proteins sequester BiP

SIGMAR1 activation: Dissociates from BiP, migrates to MAMs

Calcium modulation: Helps restore ER calcium homeostasis

Pro-survival signaling: Activates adaptive UPR pathways

See also: ER Stress and Unfolded Protein Response in Parkinson's Disease

Neuroprotection Mechanisms

Multi-Target Neuroprotection

SIGMAR1 activation provides neuroprotection through multiple interconnected pathways[9]:

Alpha-Synuclein and SIGMAR1

Emerging evidence suggests crosstalk between sigma-1 receptor function and alpha-synuclein pathology[10]:

• SIGMAR1 agonists reduce alpha-synuclein aggregation
• SIGMAR1 activation enhances autophagy-mediated alpha-synuclein clearance
• Sigma-1 receptor expression is reduced in Lewy body disease
• MAM dysfunction may promote alpha-synuclein seeding at ER-mitochondria contacts

Therapeutic Potential

Sigma-1 Receptor Agonists in PD

| Compound | Mechanism | Development Stage | Notes |
|----------|-----------|-------------------|-------|
| PRE-084 | Selective agonist | Preclinical | Strong neuroprotective data in PD models |
| SA-4503 | Agonist | Clinical trials | Improved cognition in Phase II |
| Dextromethorphan | Agonist | Repurposed | FDA-approved, BBB-penetrant |
| Donepezil | Agonist | Repurposed | Approved for AD, sigma-1 activity |

Clinical Considerations

Advantages of SIGMAR1 targeting:

• Multiple neuroprotective mechanisms
• Oral bioavailability of many agonists
• Good safety profile
• Potential disease-modifying effects

Challenges:

• Optimal dosing for CNS effects
• Receptor desensitization with chronic use
• Need for brain-penetrant selective agonists

See also: Sigma-1 Receptor Agonists for Neurodegenerative Diseases

Cross-Linking to Related Mechanisms

• Calcium Signaling Dysregulation in Parkinson's Disease
• Mitochondrial Dysfunction in Parkinson's Disease
• ER Stress and Unfolded Protein Response in Parkinson's Disease
• PINK1/Parkin Mitophagy Pathway in Parkinson's Disease
• Alpha-Synuclein Aggregation Pathway in Parkinson's Disease
• SIGMAR1 Gene
• Sigma-1 Receptor Protein
• Substantia Nigra Pars Compacta Dopamine Neurons in Parkinson's Disease

See Also

• [Calcium Signaling Dysregulation in Parkinson's Disease](/mechanisms/calcium-dysregulation-parkinsons)
• [PINK1/Parkin Mitophagy Pathway in Parkinson's Disease](/genes/pink1)
• [ER Stress and Unfolded Protein Response in Parkinson's Disease](/mechanisms/er-stress-upr-parkinsons)
• [α-Synuclein](/proteins/alpha-synuclein-protein)
• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [Alpha](/mechanisms/alpha-synuclein-aggregation-pathway)
• [SIGMAR1 Gene](/genes/sigmar1)
• [Sigma](/proteins/sigmar1-protein)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Maurice T, Su TP, The sigma-1 receptor and its role in the central nervous system (2020)](https://doi.org/10.1016/j.neuropharm.2020.108271)

[Onofrate M et al., The sigma-1 receptor: a chaperone for the pathophysiology of neurodegenerative diseases (2022)](https://doi.org/10.1016/j.tips.2022.01.007)

[Liew C et al., SIGMAR1 mutations and neurodegenerative disease (n.d.)](https://doi.org/10.1093/brain/awac133)

[Surmeier DJ et al., Dopaminergic neuron vulnerability in Parkinson's disease (2021)](https://doi.org/10.1016/j.nbd.2021.105531)

[Paillusson S et al., Mitochondria-associated membranes (MAMs) in neurodegeneration (2020)](https://doi.org/10.1016/j.jneumeth.2020.108835)

[Unknown, Guyenet SJ, Bezprozvanny I, Calcium dysregulation in Parkinson's disease (2021)](https://doi.org/10.1016/j.tins.2021.03.008)

[Grünewald A et al., Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and therapeutic approaches (2022)](https://doi.org/10.1016/j.pharmthera.2022.108205)

[Mojsa B et al., Endoplasmic reticulum stress in Parkinson's disease (2020)](https://doi.org/10.1016/j.nbd.2020.105126)

[Nguyen L et al., Neuroprotective strategies targeting sigma-1 receptor (2021)](https://doi.org/10.1016/j.neuropharm.2021.108617)

[Ouali Alami N et al., Alpha-synuclein and sigma-1 receptor in Lewy body disease (n.d.)](https://doi.org/10.1007/s00401-021-02376-4)